Clinical Trial Detail

NCT ID NCT01531361
Title Vemurafenib With Sorafenib Tosylate or Crizotinib in Treating Patients With Advanced Malignancies With BRAF Mutations
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors M.D. Anderson Cancer Center
Indications

Advanced Solid Tumor

Therapies

Sorafenib + Vemurafenib

Crizotinib + Vemurafenib

Age Groups: adult senior

Additional content available in CKB BOOST